Novartis misses Q1 revenue and EPS but maintains strong growth outlook and key product performance.

Novartis reported Q1 results below revenue and EPS estimates, yet key growth products like Kisqali, Kesimpta, Leqvio, and Pluvicto continue to perform well. Despite faster-than-expected sales erosion of Entresto in the U.S., the company reaffirmed its full-year revenue guidance, supported by easier year-over-year comparisons and a strong product pipeline. The recent acquisition of Avidity Biosciences adds promising late-stage assets, potentially boosting medium- and long-term growth prospects. Overall, the report signals confidence in Novartis's growth trajectory despite short-term challenges.